论文部分内容阅读
目的 探讨降纤酶治疗心源性脑栓塞病人的疗效和安全性。 方法 2 6例心源性脑栓塞病人均有心房纤颤病史 ,男 1 0例 ,女 1 6例 ,年龄 4 0～ 78岁 ,平均 ( 5 1 .73± 1 1 .1 9)岁。给予降纤酶 1 0 u,每日 1次静滴 ,7天为 1疗程。用药期间监测血浆纤维蛋白原、血小板计数、出凝血时间及肝肾功能。 结果 降纤酶治疗心源性脑栓塞疗效确切 ,能改善神经功能 ,总有效率为 88.4 6 % ,早期应用效果更好。无任何不良反应。 结论 降纤酶是一种安全、有效的治疗心源性脑栓塞的药物 ,宜早期、足量、长疗程应用。
Objective To investigate the efficacy and safety of defibrase in the treatment of patients with cardiogenic cerebral embolism. Methods Twenty-six patients with cardiogenic cerebral embolism had a history of atrial fibrillation. There were 10 males and 16 females aged 40 to 78 years, with an average of (51.71 ± 1.19) years. Given defibrase 10 u, daily intravenous infusion, 7 days for a course of treatment. During the monitoring of plasma fibrinogen, platelet count, clotting time and liver and kidney function. Results defibrase treatment of cardioembolic cerebral infarction exact effect, can improve nerve function, the total effective rate was 88.4%, early application effect is better. No adverse reactions. Conclusion defibrase is a safe and effective treatment of cardioembolic drugs, should be early, adequate, long course of application.